Compare · ABT vs LGND
ABT vs LGND
Side-by-side comparison of Abbott Laboratories (ABT) and Ligand Pharmaceuticals Incorporated (LGND): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and LGND operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $179.08B, about 30.1x LGND ($5.95B).
- Over the past year, ABT is down 22.7% and LGND is up 77.4% - LGND leads by 100.1 points.
- ABT has been more active in the news (8 items in the past 4 weeks vs 7 for LGND).
- ABT has more recent analyst coverage (25 ratings vs 11 for LGND).
- Company
- Abbott Laboratories
- Ligand Pharmaceuticals Incorporated
- Price
- $103.52-0.22%
- $299.53+0.30%
- Market cap
- $179.08B
- $5.95B
- 1M return
- -11.30%
- +6.76%
- 1Y return
- -22.69%
- +77.39%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 11
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Latest ABT
- Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
- Abbott declares 411th consecutive quarterly dividend
- First Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care
- Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
Latest LGND
- Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
- Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
- Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
- Director Zimmermann Martine sold $342,000 worth of shares (1,200 units at $285.00), decreasing direct ownership by 24% to 3,897 units (SEC Form 4)
- CLO & Secretary Reardon Andrew sold $1,430,434 worth of shares (5,000 units at $286.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 36,514 units (SEC Form 4)
- Amendment: Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Financial Statements and Exhibits
- Ligand to Participate in September Investor Conferences
- Chief Financial Officer Espinoza Octavio exercised 31,641 shares at a strike of $56.91 and sold $9,241,229 worth of shares (31,641 units at $292.06) as part of a pre-agreed trading plan (SEC Form 4)
- Director Haas Jason exercised 6,138 shares at a strike of $51.56 and sold $2,090,062 worth of shares (7,138 units at $292.81), decreasing direct ownership by 20% to 3,981 units (SEC Form 4)